With Spotlight on Alzheimer's Disease and Biogen, Competitors' Stocks Soar | BioSpace
Biogen's Aducanumab: A Look at the Drug's History and Recent Updates | BioSpace
FDA approves much-debated Alzheimer's drug panned by experts | AP News
The Future of Alzheimer's Treatment? Approval of Aduhelm & Other Anti-Amyloid Antibodies – Montgomery County Medical Society
FDA approves much-debated Alzheimer's drug panned by experts | AP News
Aduhelm (aducanumab) Q+A - Penn Memory Center
FDA approves Aduhelm, first new drug for Alzheimer's in 20 years, despite questions - CBS News
FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries | KFF
Congressional Probe of Alzheimer's Drug Approval Finds Fault With FDA Actions | MedPage Today
EMA gives thumbs down to Biogen's Alzheimer's drug aducanumab - Drug Discovery and Development
Press Releases – Page 2 – Global Alzheimer's Platform Foundation
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies | Biogen
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
Aduhelm safety: the data gap on aducanumab's brain swelling side effect
June 7, 2021: A Historic Day | The Long and Winding Road...
Biogen readies Alzheimer's hopeful aducanumab for U.S. launch as stateside sales plummet | Fierce Pharma
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year | Fierce Pharma
Biogen CEO on FDA approval for its Alzheimer's drug - YouTube
Aducanumab: New Medication FDA Approved for Alzheimer's Disease – Psychiatry Education Forum
Biogen's Alzheimer's drug approved by FDA, first new therapy in nearly two decades
Biogen's Alzheimer's Drug Gets FDA Approval, Mixed Reviews | The Scientist Magazine®
Congressional Investigation into Alzheimer's Drug Aduhelm Faults the F.D.A. and Biogen - The New York Times
Biogen is ready to roll on lecanemab production, CFO says
Biogen stuns with planned US FDA filing for previously scrapped Alzheimer's drug | S&P Global Market Intelligence
Biogen releases long-term Aduhelm data
Biogen Reverses Take on Aducanumab Trial Data | MedPage Today
Aducanumab: will Biogen's Aduhelm recover from its rocky start? - Pharmaceutical Technology
